Ashley Cade

Partner Intellectual Property

Washington, D.C. +1 202 389 3381

Ashley Cade

Practices

Overview

Ashley Cade is an intellectual property litigation partner, whose work focuses on patent litigation in district court and appeals before the U.S. Court of Appeals for the Federal Circuit. She holds degrees in chemistry and biochemistry, and routinely works on life sciences matters involving small molecules, pharmaceutical compositions and biologics. Ashley has experience in all stages of litigation, including pre-suit analysis, patent dance proceedings, taking and defending depositions, briefing and arguing discovery motions, and writing trial, post-trial and appeal briefs. Ashley also served as a law clerk to the Honorable Kara F. Stoll at the U.S. Court of Appeals for the Federal Circuit, and teaches a course on the Federal Circuit with Judge Stoll at The George Washington University Law School.

Representing Finch and the University of Minnesota in patent litigation brought by Ferring and Rebiotix concerning gut microbiome products.

Represented Bristol-Myers Squibb in numerous Hatch-Waxman patent infringement litigations regarding cancer therapy Sprycel® (dasatinib). Sprycel® is a cancer drug used to treat patients with chronic myelogenous leukemia and Philadelphia chromosome positive acute lymphoblastic leukemia. Cases settled during fact and expert discovery.

Represented Eagle Pharmaceuticals in patent litigation brought by Par Pharma companies involving Eagle’s ANDA for the generic version of Par's Vasostrict® (vasopressin injection) for the treatment of hypotension/low blood pressure in patients experiencing vasodilatory shock. After a bench trial, the Court found that Eagle’s ANDA product did not infringe Par’s asserted patents. The Federal Circuit affirmed the district court’s judgment of noninfringement in a precedential opinion.

Represented Teva in patent litigation brought by Janssen involving Teva’s ANDA for the generic version of Invega Sustenna® (paliperidone palmitate) for the treatment of schizophrenia and schizoaffective disorder. The Federal Circuit vacated the district court’s judgment of no invalidity in a precedential opinion. 

Represented Teva in patent litigation brought by Celgene involving Teva’s ANDA for the generic version of Celgene’s Pomalyst® (pomalidomide). Teva obtained favorable settlement during expert discovery after years of litigation.

Represented biosimilar drug maker in all phases of patent dance proceedings under the BPCIA and early stages of litigation.

Represented Samsung Electronics in patent litigation brought by Greenthread concerning semiconductor devices. Case settled during expert discovery.

Law ClerkHonorable Kara F. StollUnited States Court of Appeals for the Federal Circuit2021–2022

More

Thought Leadership

Co-Author, “Implications of inter partes review proceedings on biotech/pharma litigation,” Pharmaceutical Patent Analyst, Vol. 8, No. 3, pp. 65–70, June 2019.

Note, “Mistakes in Patent Law: Reforming the Reissue Statute in Light of Alice,” The American Intellectual Property Law Association Quarterly Journal, 2018.

Credentials

Admissions & Qualifications

  • 2021, District of Columbia
  • 2019, New York
  • Registered to practice before the United States Patent and Trademark Office

Courts

  • United States Court of Appeals for the Federal Circuit
  • United States District Court for the Southern District of New York

Education

  • The George Washington University Law SchoolJ.D.with Honors2018

    Executive Notes Editor, The American Intellectual Property Law Association Quarterly Journal

    Pro Bono Award

  • University of Michigan-DearbornB.S., Chemistry & Biochemistrywith High Distinction2015

    Chancellor’s Scholar (Full Tuition Merit Scholarship)

    William J. Branstrom Freshman Award